Despite this limitation, our study is clinically relevant because it reveals the correlation between poor prognosis and FOXD1 expression levels in basal-like primary tumors and indicates that FOXD1 maintains specific enhancer–gene programs associated with tumor progression. The gene discussed is FOXD1; the disease is neoplasm.